The Tumor Microenvironment is Complex. Your Assays Shouldn’t Be.
The Tumor Microenvironment is Complex.
Your Assays Shouldn’t Be.
Whole Slide Imaging
Unbiased Samples
Visualize all cells
Spatial Multiplexing
High Resolution
Characterize each cell type
Single-Cell Phenotyping
In-Depth Analysis
Determine cell interaction
InSituPlex® Technology - The Ultivue Difference
Platform Agnostic
A simplified workflow that utilizes your existing histology equipment, scanners and image analysis software
Same Day Results
High throughput assays for fast staining, scanning, and image analysis
Marker Co-localization
Investigate complex phenotypes through coexpression of markers on single cells
Differential Expression
Identify high and low abundance markers
UltiMapper I/O Kits
Off-the-shelf multiplex IHC panels
Off the shelf fully optimized fluorescent multiplex IHC panels for same day staining to results.
U-VUE Biomarker Menu
Custom Marker Kits
Develop your own InSituPlex panel from our growing portfolio of verified biomarkers
Products
UltiMapper I/O Kits
Off the shelf fully optimized fluorescent multiplex IHC panels for same day staining to results.
U-Vue Biomarker Menu
Custom Marker Kits
Develop your own InSituPlex panel from our growing portfolio of verified biomarkers
Services and Programs
CRO Services + Biomarker Programs
With speed and flexibility at heart, both our Staining and Imaging Services and our Biomarker Programs offer highly customizable panels to accelerate your research.
InSituPlex in Action
Poster - ASCO 2019
InSituPlex used to assess immune checkpoint inhibitor targeted CD8 activation and tumor co-localization
Poster - AACR 2019
Deep spatial immuno-profiling through high biomarker colocalization in FFPE tumor tissue samples
Recent news
Ultivue and Indivumed partner for research and drug development in personalized oncology
Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence
CAMBRIDGE, Mass, July 22, 2020 – –Ultivue, Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging.
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services
Kassel, Germany and Cambridge, MA, USA November 7, 2019 – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays.